TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: OUCC suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of gonadotrophin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of frozen embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: emergency department revisits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute walking distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine usage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year melanoma-specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Pelvic discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visuoperceptive task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence and aggravation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Operating room time savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total intraoperative direct cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MBG 3 frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of MACE
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of preeclampsia (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: overall body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WHO-5 total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in office systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum concentrations of transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC(0-24)) of mirtazapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of mirtazapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state plasma levels of mirtazapine (C(ss,min) and C(ss,av))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement (VAS, SANE, QuickDASH scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability (high-frequency, low-frequency, low-frequency/high-frequency ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of ulcers closed by 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to closure for ulcers achieving closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Written examination performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-contentment with learning experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Threshold tumor volume for index tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Contraction amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of secondary contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Latencies of the evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of subcutaneous sumatriptan
Endpoint domain: Adverse events/effects
Primary endpoint: Speed of action of subcutaneous sumatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS improvement in arm, finger and upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T vector amplitude change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain and activity limitation at 1-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chronic discomfort in open VHR
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: lesion-to-brain ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss among adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic venous thromboembolism recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Exercise tolerance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days of respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Affected side leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean decline of HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undetectable HBV DNA (<20 IU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-inflammatory effect on UV-induced erythemas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: recovery time of bowel sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative and anaesthesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: patient and surgeon satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak blood ethanol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the blood ethanol concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dynamic Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hypersensitivity of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores for acceptance for future colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: preabortion psychological distress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious bacterial infection
Endpoint domain: Adverse events/effects
Primary endpoint: wedge pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hair loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Anagen/telogen ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of ISNCSCI scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of plasma 1-deoxySL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: competition times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in AAdSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: VAS and FPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systolic blood pressure increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean blood pressure increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of diagnostic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients whose parasitaemia cleared by day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cure rates on days 21 and 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of children carrying gametocytes during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disability improvement (ODI score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival after PMRT
Endpoint domain: Mortality/survival
Primary endpoint: Locoregional recurrence control after PMRT
Endpoint domain: Mortality/survival
Primary endpoint: Clinical events (deaths, reinfarctions, chest pains requiring hospitalization)
Endpoint domain: Mortality/survival
Primary endpoint: Total median individual costs
Endpoint domain: Resource use
Primary endpoint: QT dispersion (QTcd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in total abdominal adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subcutaneous adipose tissue (SAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional cancers detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correct assessment of breasts without additional cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cancer knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain intensity at TrPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TrPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of referred pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of diarrhea
Endpoint domain: Mortality/survival
Primary endpoint: maximal dilation of coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean number of micturitions/24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intranasal Discomfort Score (INDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative death- and MACE-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in non-psychotic depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS score for abdominal pain at 8 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct classification rate for aMCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor evoked potentials (MEP) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CMC (corticospinal conduction) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PI area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: perceived efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in postvoid residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: butorphanol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of successfully delivered doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Left Ventricular Diastolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of closed vein segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: frequency of postthrombotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rates of complete recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Inattention score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quadriceps RMSsum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total mechanical work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term medical expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decline in SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum IgG LPS antibodies titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk of post-first shock asystole or persistent VF
Endpoint domain: Mortality/survival
Primary endpoint: myocardial injury as determined by ST segment deflection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional status (Lequesne's index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for transfusion of donor blood
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: contrast dye spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intrinsic ligament injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete scapholunate ligament rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative pain levels in the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption in the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels 4 weeks after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return rate for TB skin test reading
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gastrointestinal symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of worsening renal function (WRF) within 7 days from admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Success rate of transtracheal cannula placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of emergency tracheotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of gastrointestinal perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiovascular death, cerebral stroke and myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral stroke incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in blood circulation in vertebral tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninferiority of LAA occlusion compared to NOAC treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to the third wheezing episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days with respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of natural pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean and peak pressure gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Total Peripheral Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin Conductance Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with the Web site
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: event-free graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: tumor volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bony union rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pre-operative neck pain subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibriocidal antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HRQOL (EQ-5D utility score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Onset of local anesthesia (LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experience score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination inhibition (HI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H5-specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived postoperative pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Circulating mitochondrial DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remaining culture-positive after 2 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of prandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in oxidative stress markers (MDA and oxLDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of urinary biomarkers for recent drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection times for urinary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum EtG concentrations compared to EtS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of actively inflamed joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SAP
Endpoint domain: Mortality/survival
Primary endpoint: Swallowing function improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient engagement with attention to in-session emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of lifestyle intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores 30min post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional analgesic needed during the postoperative period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Death in children with RSV infection
Endpoint domain: Mortality/survival
Primary endpoint: Pain level during the first 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexion after 6 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: deportment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: permanent product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of glaucoma cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perforation of a duodenal ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MH rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FCP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes